Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286602 | 0.97 | LMNA (0.46) | LMNAHIF1AEPAS1 | |
| SCHEMBL9051389 | 0.94 | LMNA (0.48) | LMNAHIF1AEPAS1KDM1APTPN1 | |
| SCHEMBL11593566 | 0.94 | LMNA (0.48) | LMNAHIF1AEPAS1KDM1APTPN1 | |
| SCHEMBL8858237 | 0.94 | LMNA (0.48) | LMNAHIF1AEPAS1KDM1APTPN1 | |
| SCHEMBL7067432 | 0.94 | LMNA (0.48) | LMNAHIF1AEPAS1KDM1APTPN1 | |
| SCHEMBL11444896 | 0.94 | LMNA (0.48) | LMNAHIF1AEPAS1KDM1APTPN1 | |
| SCHEMBL16872425 | 0.94 | LMNA (0.48) | LMNAHIF1AEPAS1KDM1APTPN1 | |
| SCHEMBL6905821 | 0.94 | LMNA (0.48) | LMNAHIF1AEPAS1KDM1APTPN1 | |
| SCHEMBL21219896 | 0.94 | LMNA (0.48) | LMNAHIF1AEPAS1KDM1APTPN1 | |
| SCHEMBL28868791 | 0.94 | LMNA (0.45) | LMNAKDM1APTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149479-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-8557991-B2 | Process for preparing enantiomerically pure indolopyridines | 4SC AG (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8044065-B2 | Benzothienopyridines for use as inhibitors of Eg5 kinesin | ALTANA PHARMA AG (DE) | 2011-10-25 | — | — | US | disclosed |
| US-20110257221-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257169-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-8003798-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | NYCOMED GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| EP-2268644-B1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2011-08-17 | — | — | EP | disclosed |
| EP-1797098-B1 | 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS | NYCOMED GMBH (DE) | 2011-05-04 | — | — | EP | disclosed |
| US-20110077404-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | 4SC AG (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20110027226-A1 | INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) | 4SC AG (DE) | 2011-02-03 | — | — | US | disclosed |
| EP-1075477-A1 | NOVEL N-OXIDES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-02-14 | — | — | EP | disclosed |
| EP-1075476-A1 | NOVEL BENZIMIDAZOLES AND BENZOXAZOLES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-02-14 | — | — | EP | disclosed |
| WO-2000012501-A1 | BENZONAPHTHYRIDINE-N-OXIDES COMPRISING A PDE3 AND PDE4 INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999064414-A1 | BENZAMIDES WITH TETRAHYDROFURANYLOXY SUBSTITUTENTS AS PHOSPHODIESTERASE 4 INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999057118-A1 | NOVEL N-OXIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999057115-A1 | NOVEL BENZIMIDAZOLES AND BENZOXAZOLES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-11-11 | — | — | WO | disclosed |
| EP-0228959-B1 | AMINOSTYRYL COMPOUND, LEUKOTRIENE ANTAGONISTIC COMPOSITION CONTAINING THE SAME AS EFFECTIVE INGREDIENTS AND METHOD OF ANTAGONIZING SRS BY EMPLOYING THE SAME | MITSUBISHI KASEI CORPORATION (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4749701-A | Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing SRS by employing the same | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1988-06-07 | — | — | US | disclosed |
| EP-0228959-A2 | Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing SRS by employing the same | MITSUBISHI KASEI CORPORATION (JP) | 1987-07-15 | — | — | EP | disclosed |
| US-4338315-A | RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077404-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | GRIK5, CYP3A5, GRK5 | LMNA 3580/4885HIF1A 4355/4885EPAS1 1893/4885 |
| US-20110027226-A1 | INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) | KIF5A, KIF5C, KIF5B | LMNA 2432/4885HIF1A 4717/4885EPAS1 3938/4885 |
| US-20110257221-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | LMNA 4157/4885HIF1A 3248/4885EPAS1 211/4885 |
| US-20110257169-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | LMNA 4157/4885HIF1A 3248/4885EPAS1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.